Sonnet BioTherapeutics Holdings Debt to Equity

Sonnet BioTherapeutics Holdings (SONN) currently reports a debt-to-equity ratio of 0.0. That is above the Consumer Staples sector average of -0.83. Use the charts on this page to explore Sonnet BioTherapeutics Holdings's debt-to-equity ratio history and peer comparisons.

Sonnet BioTherapeutics Holdings's debt-to-equity ratio of 0.0 is higher than the Consumer Staples sector average of -0.83. That is roughly 100.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates Sonnet BioTherapeutics Holdings's market price to a fundamental measure such as earnings, sales, or book value. At 0.0, SONN can look expensive or cheap only in context — versus its own history, growth rate, and Consumer Staples peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of 0.0, then check the historical chart for trend and the peer comparison chart for relative positioning. The Consumer Staples average is -0.83. From there, open related valuation or income-statement pages for Sonnet BioTherapeutics Holdings, and consider following SONN for alerts when major investors trade the stock.

Sonnet BioTherapeutics Holdings is classified in the Consumer Staples sector. On debt-to-equity ratio, it currently shows 0.0 versus a sector average near -0.83. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Consumer Staples are usually more informative than comparing SONN with unrelated industries.